Novartis AG (LTS:0K9E)
$ 104.7 0 (0%) Market Cap: 209.81 Bil Enterprise Value: 227.95 Bil PE Ratio: 12.53 PB Ratio: 5.07 GF Score: 80/100

Novartis AG at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 04:40PM GMT
Release Date Price: $88.66
Richard Vosser
JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon. Welcome to the 39th JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. It gives me great pleasure to introduce Vas Narasimhan, CEO of Novartis, for this presentation.

Before I hand over to Vas, I'd remind you that if you would like to ask a question during the Q&A portion, and you can use the Q&A function at any time on the associated section of the website, and I'll read your question out at the appropriate time.

With that, I'd like to welcome Vas to the conference. Vas, over to you.

Vasant Narasimhan
Novartis AG - CEO

Thank you, Richard, and thanks, everyone, for joining today. I'd like to give you an update on our progress on our strategy for Novartis and give you some of the insights on how we progress over the recent years on delivering both on our operational performance but, more importantly, on our longer-term strategy to deliver consistent growth, consistent innovation and be a leading medicines

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot